Work

Evaluation of the ERα agonist, GTx-758 (250 mg daily), in men with metastatic (mCRPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.7_suppl.201

Authors: Evan Y. Yu, Michael L. Hancock, Tamas Babicz, William J. Aronson, Zsuzsanna Papai, Lajos Geczi, Robert H. Getzenberg

Institutions: Fred Hutch Cancer Center, GTx (United States), University of California, Los Angeles, VA Greater Los Angeles Healthcare System, National Institute of Oncology

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2497423774

Cites:

Cited by:

Related to: 10